Used primarily in research settings as a potent and selective inhibitor of monoamine oxidase B (MAO-B), this compound shows promise in the development of therapies for neurodegenerative disorders such as Parkinson’s disease. By inhibiting MAO-B, it helps increase dopamine levels in the brain, which can improve motor function and slow disease progression. Its unique structure allows for high blood-brain barrier penetration and prolonged activity, making it a candidate for once-daily dosing in preclinical models. Additionally, due to its stereospecific design, it exhibits fewer off-target effects compared to non-selective MAO inhibitors, reducing the risk of dietary interactions and adverse events. It is not approved for clinical use but serves as a valuable tool compound in neuroscience and psychopharmacology research.